{"aliases":[{"type":"CodeName","name":"PR-171"},{"type":"USBrandName","name":"Kyprolis"},{"type":"ChemicalStructureName","name":"(2S)-N-((1S)-1-benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide"},{"type":"CASRegistryName","name":"868540-17-4"},{"type":"ForeignBrandName","name":"Carfilnat"},{"type":"Abbreviation","name":"CFZ"}],"definition":{"html":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","text":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/carfilzomib","text":"Carfilzomib"},"nciConceptId":"C52196","nciConceptName":"Carfilzomib","termId":459751,"name":"carfilzomib","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"carfilzomib"}